Company / Shareholders' Equity
Corbus Pharmaceuticals Holdings, Inc. Shareholders' Equity History
FY2015-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$69.1M
FY2022
5-year range
$6.2M / $69.1M
FY2018-FY2022
Trend
+52.6%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $6M to $69M over the past 2 years.
Based on SEC 10-K filings.
$69M in FY2022 with a 5-year CAGR of +50.6%.
Improved from $6M to $69M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +35.9%
- 5-Year CAGR
- +50.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +50.6%, indicating consistent growth.
- In FY2022, shareholders' equity increased 52.6% year-over-year.
- Lowest shareholders' equity in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -12.48 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $69.1M | +52.6% |
| FY2021 | $45.3M | +635.3% |
| FY2020 | $6.2M | -77.6% |
| FY2019 | $27.5M | -52.4% |
| FY2018 | $57.8M | +547.9% |
| FY2017 | $8.9M | +52.1% |
| FY2016 | $5.9M | +0.0% |
| FY2015 | $5.9M | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026